Abstract:A series of ruthenium(II) complexes containing andrographolide‐based hydrazide derivatives were synthesized and characterized. The anticancer nature of the synthesized compounds has examined with MTT assay, staining assays, and flow cytometry analysis. All the ligands and complexes showed potent anticancer activity. A new set of andrographolide‐appended hydrazide derivatives (AFC, AGC, and ATC) were prepared from the reaction of andrographolide with furan‐2‐carboxylic acid hydrazide (AFC), pyridine‐3‐carboxylic acid hydrazide (AGC), and thiophene 2‐carboxylic acid hydrazide (ATC), and their corresponding ruthenium(II) complexes (Ru‐AFC, Ru‐AGC, and Ru‐ATC) were synthesized by the direct reaction of [RuCl2(η6‐p‐cymene)]2 with ligands in dichloromethane under stirring condition. The compounds were analyzed by elemental analysis, IR, UV‐Vis, 1H NMR, and ESI‐MS spectrometric techniques, and the obtained spectral data revealed that the ligands coordinated to Ru(II) ion through their enone oxygen and amine nitrogen. Antioxidant activities of the ligands and complexes were calculated against DPPH•, ABTS•+, O2−, and NO• free radicals and their results were compared with standard antioxidants. The cytotoxic activity of the synthesized ligands and complexes toward A549 and HeLa cell lines was evaluated using MTT method (MTT = 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide). Among the compounds, the complex Ru‐AGC showed better cytotoxic effect against A549 and HeLa cancer cells with IC50 values of 4.75 ± 0.17 and 6.32 ± 0.26 μM, respectively. Further, the nontoxic nature of the compounds was confirmed by using human umbilical vein endothelial (HUVEC) cells. The apoptosis was inspected with AO/EB and DAPI staining methods; further, the percentages of the apoptotic and necrotic cells were determined by flow cytometry. Overall, the biological activities of our ruthenium(II)‐arene complexes were found to be more potent than their parent ligands due to chelation, and among the complexes, Ru‐AGC showed better activity due to the presence of pyridine ring in the N‐terminal position of the ligand. The obtained results highlighted the strong possibility to develop highly active ruthenium complexes as anticancer agents.

Ru(II)‐Nitrophenylhydrazine/Chlorophenylhydrazine Complexes: Nanoarchitectonics, Biological Evaluation and In silico Study

Synthesis and characterization of novel Ru(III) complexes of 2‐aminopyrazine: Interaction with biomolecules, antineoplastic activity, and computational investigation

Exploring the potential of ruthenium(ii)–phosphine–mercapto complexes as new anticancer agents

New organoruthenium compounds with pyrido[2′,3′:5,6]pyrazino[2,3-f][1, 10]phenanthroline: synthesis, characterization, cytotoxicity, and investigation of mechanism of action

Dinuclear arene ruthenium(II) arylthiourea complexes: Synthesis, structure, cancer cell growth inhibition and apoptosis induction studies

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Ruthenium(II)-N-alkyl phenothiazine complexes as potential anticancer agents

Biomolecular Interactions and Anticancer Mechanisms of Ru(II)-Arene Complexes of Cinnamaldehyde-Derived Thiosemicarbazone Ligands: Analysis Combining In Silico and In Vitro Approaches

New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies

Exploring the Cytotoxicity of Dinuclear Ru(II) p-cymene Complexes Appended N,N'-Bis(4-substituted benzoyl)hydrazines: Insights into the Mechanism of Apoptotic Cell Death

Synthesis, characterization, and anticancer activity of Ru( p -cymene) complexes bearing pyrazolyl–pyridine type ligands

Study on antitumor activity of three ruthenium arene complexes in vitro

Ru(II)-Diphosphine/N,S-Mercapto Complexes and Their Anti-melanoma Properties

Coumarin‐modified ruthenium complexes: Synthesis, characterization, and antiproliferative activity against human cancer cells

Mechanistic Studies of Arene-Ruthenium(II) Complexes with Carbothioamidopyrazoles as Alternative Cancer Drugs

Ruthenium p-Cymene Complexes Incorporating Substituted Pyridine-Quinoline-Based Ligands: Synthesis, Characterization, and Cytotoxic Properties

Organometallic Ru(II), Rh(III) and Re(I) complexes of sterane-based bidentate ligands: Synthesis, solution speciation, interaction with biomolecules and anticancer activity

New Organoruthenium(II) Complexes Containing Andrographolide‐Appended Hydrazide Derivatives: Synthesis, Spectral Characterization, Anticancer Evaluation

Bioactive ruthenium(II)-arene complexes containing modified 18β-glycyrrhetinic acid ligands.

Synthesis, Cytotoxicity, and Biomacromolecule Binding: Three Isomers of Nitrosylruthenium Complexes with Bidentate Bioactive Molecules As Co-Ligands

Unprecedented Formation Of Organo-Ruthenium(Ii) Complexes Containing 2-Hydroxy-1-Naphthaldehyde S-Benzyldithiocarbazate: Synthesis, X-Ray Crystal Structure, Dft Study And Their Biological Activities In Vitro